WGS
GeneDx Holdings Corp.
NASDAQ: WGS · HEALTHCARE · DIAGNOSTICS & RESEARCH
$34.71
+0.58% today
Updated 2026-05-06
Market cap
$1.91B
P/E ratio
—
P/S ratio
4.48x
EPS (TTM)
$-0.73
Dividend yield
—
52W range
$55 – $171
Volume
1.0M
GeneDx Holdings Corp. (WGS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $196.17M | $179.32M | $212.19M | $234.69M | $202.57M | $305.45M | $427.54M |
| Revenue growth (YoY) | — | -8.6% | +18.3% | +10.6% | -13.7% | +50.8% | +40.0% |
| Cost of revenue | $113.39M | $175.30M | $228.80M | $261.44M | $112.56M | $111.05M | $129.37M |
| Gross profit | $82.78M | $4.03M | $-16.60M | $-26.75M | $90.01M | $194.40M | $298.17M |
| Gross margin | 42.2% | 2.2% | -7.8% | -11.4% | 44.4% | 63.6% | 69.7% |
| R&D | $34.91M | $72.70M | $105.16M | $86.20M | $58.27M | $45.72M | $72.03M |
| SG&A | $29.48M | $100.74M | $205.99M | $216.17M | $133.75M | $101.11M | $150.82M |
| Operating income | $-30.41M | $-241.99M | $-446.15M | $-667.65M | $-180.60M | $-23.21M | $-11.80M |
| Operating margin | -15.5% | -134.9% | -210.3% | -284.5% | -89.2% | -7.6% | -2.8% |
| EBITDA | $-22.51M | $-227.13M | $-220.75M | $-398.20M | $-136.46M | $-1.26M | $6.63M |
| EBITDA margin | -11.5% | -126.7% | -104.0% | -169.7% | -67.4% | -0.4% | 1.5% |
| EBIT | $-28.92M | $-238.87M | $-242.56M | $-457.51M | $-170.19M | $-23.21M | $-18.60M |
| Interest expense | $783000.00 | $2.47M | $2.83M | $3.21M | — | $3.03M | $2.54M |
| Income tax | $1.29M | $5.10M | $21.57M | $-49.05M | $-926000.00 | $-343000.00 | — |
| Effective tax rate | -4.5% | -2.2% | -9.6% | 8.2% | 0.5% | 0.7% | 0.0% |
| Net income | $-29.70M | $-241.34M | $-245.39M | $-548.98M | $-175.77M | $-52.29M | $-21.02M |
| Net income growth (YoY) | — | -712.5% | -1.7% | -123.7% | +68.0% | +70.3% | +59.8% |
| Profit margin | -15.1% | -134.6% | -115.6% | -233.9% | -86.8% | -17.1% | -4.9% |